NO20031745L - Inhibisjon av vekstfaktoravhengigheten til tumorceller - Google Patents

Inhibisjon av vekstfaktoravhengigheten til tumorceller

Info

Publication number
NO20031745L
NO20031745L NO20031745A NO20031745A NO20031745L NO 20031745 L NO20031745 L NO 20031745L NO 20031745 A NO20031745 A NO 20031745A NO 20031745 A NO20031745 A NO 20031745A NO 20031745 L NO20031745 L NO 20031745L
Authority
NO
Norway
Prior art keywords
inhibition
tumor cells
growth factor
factor dependence
dependence
Prior art date
Application number
NO20031745A
Other languages
English (en)
Norwegian (no)
Other versions
NO20031745D0 (no
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051609A external-priority patent/DE10051609A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20031745L publication Critical patent/NO20031745L/no
Publication of NO20031745D0 publication Critical patent/NO20031745D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20031745A 2000-10-18 2003-04-15 Inhibisjon av vekstfaktoravhengigheten til tumorceller NO20031745D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24101000P 2000-10-18 2000-10-18
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen
PCT/EP2001/012004 WO2002032429A2 (en) 2000-10-18 2001-10-17 Use of inhibitors of progesterone receptor for treating cancer

Publications (2)

Publication Number Publication Date
NO20031745L true NO20031745L (no) 2003-04-15
NO20031745D0 NO20031745D0 (no) 2003-04-15

Family

ID=26007397

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031745A NO20031745D0 (no) 2000-10-18 2003-04-15 Inhibisjon av vekstfaktoravhengigheten til tumorceller

Country Status (26)

Country Link
EP (1) EP1414465B1 (ko)
JP (1) JP4335525B2 (ko)
KR (1) KR20030044006A (ko)
CN (1) CN1311833C (ko)
AT (1) ATE339208T1 (ko)
AU (2) AU1595802A (ko)
BG (1) BG107745A (ko)
BR (1) BR0114677A (ko)
CA (1) CA2423013A1 (ko)
CY (1) CY1106289T1 (ko)
CZ (1) CZ299945B6 (ko)
DE (1) DE60123138T2 (ko)
DK (1) DK1414465T3 (ko)
EA (1) EA005945B1 (ko)
EE (1) EE200300156A (ko)
ES (1) ES2272561T3 (ko)
HK (1) HK1071697A1 (ko)
HR (1) HRP20030386A2 (ko)
HU (1) HUP0301461A3 (ko)
IL (2) IL154974A0 (ko)
MX (1) MXPA03002953A (ko)
NO (1) NO20031745D0 (ko)
NZ (1) NZ545965A (ko)
PL (1) PL366415A1 (ko)
SK (1) SK4752003A3 (ko)
WO (1) WO2002032429A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006054535A1 (de) * 2006-11-15 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Progesteronrezeptorantagonisten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
FR2789393B1 (fr) * 1999-02-05 2001-10-12 Centre Nat Rech Scient Lactol steroidique

Also Published As

Publication number Publication date
KR20030044006A (ko) 2003-06-02
EP1414465A2 (en) 2004-05-06
WO2002032429A3 (en) 2004-02-19
HUP0301461A2 (hu) 2003-10-28
HRP20030386A2 (en) 2005-04-30
JP4335525B2 (ja) 2009-09-30
AU2002215958B2 (en) 2006-08-17
EE200300156A (et) 2003-08-15
AU1595802A (en) 2002-04-29
WO2002032429A2 (en) 2002-04-25
DE60123138T2 (de) 2007-09-13
HK1071697A1 (en) 2005-07-29
EP1414465B1 (en) 2006-09-13
PL366415A1 (en) 2005-01-24
IL154974A0 (en) 2003-10-31
CA2423013A1 (en) 2002-04-25
BG107745A (bg) 2004-01-30
CN1311833C (zh) 2007-04-25
DE60123138D1 (de) 2006-10-26
CY1106289T1 (el) 2011-10-12
NO20031745D0 (no) 2003-04-15
JP2004513094A (ja) 2004-04-30
HUP0301461A3 (en) 2010-01-28
SK4752003A3 (en) 2003-10-07
DK1414465T3 (da) 2007-01-29
BR0114677A (pt) 2003-10-07
MXPA03002953A (es) 2003-08-07
EA200300468A1 (ru) 2003-10-30
ES2272561T3 (es) 2007-05-01
CZ299945B6 (cs) 2008-12-29
NZ545965A (en) 2007-09-28
ATE339208T1 (de) 2006-10-15
EA005945B1 (ru) 2005-08-25
AU2002215958C1 (en) 2002-04-29
IL154974A (en) 2007-05-15
CN1551772A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
NO20005255D0 (no) Pyrazolpyrimidin-CGMPPDE5-inhibitorer for behandling av seksuell dysfunksjon
DK1305286T3 (da) Cyclopentanoindoler, præparater indeholdende sådanne forbindelser og fremgangsmåder til behandling
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
MXPA02005844A (es) Inhibidores de cinasas de proteina.
NL300242I1 (nl) Mega-carboxyaryl gesubstitueerde difenylureums alsraf kinaseremmers.
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
MY122020A (en) Use of gabab receptor agonists as reflux inhibitors
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
NO20003600L (no) Kalium kanal inhibitorer
EA199900373A2 (ru) Фармацевтические композиции
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
YU30003A (sh) Inhibicija zavisnosti faktora rasta na ćelije tumora
ATE443044T1 (de) Tace inhibitoren
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
DE50309381D1 (de) Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen
CY1111289T1 (el) Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη
AU2002228913A1 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application